Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase Ciota-mediated attenuation of p38 MAP kinase signaling

R M BaldwinI A J Lorimer


Glioblastoma multiforme is an aggressive form of brain cancer that responds poorly to chemotherapy and is generally incurable. The basis for the poor response of this cancer to chemotherapy is not well understood. The atypical protein kinases C (PKCiota and PKCzeta) have previously been implicated in leukaemia cell chemoresistance. To assess the role of atypical PKC in glioblastoma cell chemoresistance, RNA interference was used to deplete human glioblastoma cells of PKCiota. Transfection of cells with either of two different RNA duplexes specific for PKCiota caused a partial sensitisation to cell death induced by the chemotherapy agent cisplatin. To screen for possible mechanisms for PKCiota-mediated chemoresistance, microarray analysis of gene expression was performed on RNA from glioblastoma cells that were either untreated or depleted of PKCiota. This identified sets of genes that were regulated either positively or negatively by PKCiota. Within the set of genes that were negatively regulated by PKCiota, the function of the gene coding for GMFbeta, an enhancer of p38 mitogen-activated protein kinase (MAP kinase) signaling, was investigated further, as the p38 MAP kinase pathway has been previously identified as a key mediat...Continue Reading


May 1, 1989·Research in Immunology·M W KieranA Israel
Jan 1, 1997·Acta neurochirurgica·Y SawamuraH Abe
Sep 1, 1997·Nucleic Acids Research·S F AltschulD J Lipman
Nov 5, 1997·The Journal of Biological Chemistry·N R Murray, A P Fields
Mar 21, 2000·Biochimica Et Biophysica Acta·M W Mayo, A S Baldwin
Feb 7, 2001·Molecular and Cellular Biology·M T Diaz-Meco, J Moscat
Mar 17, 2001·Nature Reviews. Genetics·E C Holland
Apr 20, 2001·Proceedings of the National Academy of Sciences of the United States of America·V G TusherG Chu
May 7, 2002·EMBO Reports·Moran BenharAlexander Levitzki
Jul 26, 2002·Oncogene·Marc A AntonyakAlbert J Wong
Aug 22, 2002·Current Cancer Drug Targets·I A J Lorimer
Dec 17, 2002·Oncogene·Moran BenharAlexander Levitzki
May 15, 2003·Proceedings of the National Academy of Sciences of the United States of America·Dimitri SemizarovStephen W Fesik
Jun 25, 2003·Oncogene·Javier Hernández LosaRicardo Sánchez-Prieto
Aug 9, 2003·The Journal of Endocrinology·D R Brigstock
Feb 26, 2004·Biochimica Et Biophysica Acta·Masaaki InagakiKiyofumi Asai
Jul 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Isabelle Sansal, William R Sellers
Aug 24, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Rachel S SoloffStephen M Hedrick
Sep 9, 2004·American Journal of Physiology. Renal Physiology·Marie H HaniganMaia G Lapus
Oct 6, 2004·Genome Biology·Robert C GentlemanJianhua Zhang
Oct 12, 2004·Neurotoxicology·Byung Kwan ChoiYong Keun Kim
Oct 14, 2004·Australian Veterinary Journal·S M FearnsideJ R Powe
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
May 7, 2005·EMBO Reports·Isabel García-CaoManuel Serrano
Sep 24, 2005·American Journal of Nephrology·Frederic ClaytonRichard L Siegler

❮ Previous
Next ❯


May 27, 2009·Expert Reviews in Molecular Medicine·Alvin J X LeeCharles Swanton
Nov 29, 2011·Oncogene·J A PagetI A J Lorimer
Jan 24, 2008·Oncogene·R M BaldwinI A J Lorimer
Jun 13, 2009·Proceedings of the National Academy of Sciences of the United States of America·Ryo UedaHideho Okada
Jun 17, 2010·PloS One·Ian J Restall, Ian A J Lorimer
Sep 3, 2010·Journal of Nucleic Acids·Alakananda Basu, Soumya Krishnamurthy
Jun 27, 2014·Neurochemical Research·Andrea N McCrayMildred Acevedo-Duncan
May 28, 2013·In Vitro Cellular & Developmental Biology. Animal·Mahdieh Sadat TaghaviGholamreza Javadi
Sep 21, 2012·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Sohila ZadranHomera Zadran
Jul 26, 2015·Cell Cycle·Ian J RestallIan A J Lorimer
Mar 6, 2007·Critical Reviews in Oncology/hematology·David J Stewart
Jan 24, 2008·Cell Proliferation·R PatelM Acevedo-Duncan
Nov 1, 2011·Neuropathology and Applied Neurobiology·R ThangavelA Zaheer
Oct 15, 2010·Journal of Cellular Physiology·Nicole R MurrayAlan P Fields
Oct 29, 2009·Journal of Neurochemistry·Long Tai ZhengKyoungho Suk
Jul 25, 2013·Cell Adhesion & Migration·Adrian Gunaratne, Gianni M Di Guglielmo
Jan 30, 2013·Cancer Biology & Therapy·Anália do CarmoMaria Celeste Lopes
Apr 28, 2009·Biochimica Et Biophysica Acta·Priya SrideviStephen Alexander
Nov 16, 2013·Biochemical Pharmacology·Peter J ParkerAlan P Fields
Sep 8, 2010·Molecular Cancer·R Mitchell BaldwinIan A J Lorimer
Jul 23, 2016·Frontiers in Cell and Developmental Biology·Jesús García-CanoRicardo Sánchez-Prieto
Sep 18, 2012·Acta Pharmacologica Sinica·Jing FanQi-Min Zhan
Dec 8, 2006·Neurochemical Research·Asgar ZaheerRamon Lim
May 21, 2017·Scientific Reports·Ritesh KumarIan A J Lorimer
Sep 3, 2019·Cancer Cell·Miguel Reina-CamposJorge Moscat
Dec 17, 2014·Journal of Cell Science·Adrian GunaratneGianni M Di Guglielmo

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.